Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as
(DCAL)
XNSE:DCAL, XBOM:DCAL
Dishman Carbogen Amcis Ltd Q4FY24; 6% rise in Revenue
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as
Dishman Carbogen Amcis Ltd Q2FY24; 4% fall in Revenue
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as
Dishman Carbogen Amcis Ltd Q1FY24; 325% rise in Profits
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as
Earnings Summary Of Dishman Carbogen Amcis Limited For Q4 FY23
Dishman Carbogen Amcis Limited is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of
Dishman Carbogen Amcis Ltd (DCAL) Q2 FY22 Earnings Concall Transcript
Dishman Carbogen Amcis Ltd (NSE: DCAL) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Arpit Vyas -- Global Managing Director Pascal Villemagne -- Vice